Alleviating effects of morin against experimentally-induced diabetic osteopenia

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Abuohashish, Hatem M ^a   Al Rejaie, Salim S ^a   Al Hosaini, Khaled A ^a   Parmar, Mihir Y ^a   Ahmed, Mohammed M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Diabetic osteopenia; Inflammation; Micro CT; Morin; Oxidative stress

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; GLUCOSE; GLUTATHIONE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MORIN; OSTEOCALCIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETIC OSTEOPENIA; DRUG EFFECT; GLUCOSE BLOOD LEVEL; MALE; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

EID: 84873265324     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-5     Document Type: Article

References (56)

1. Osteoporosis among patients with type 1 and type 2 diabetes. Rakel A, Sheehy O, Rahme E, LeLorier J, Diabetes Metab 2008 34 193 205 10.1016/j.diabet.2007.10.008 18308607
2. Role of oxidative stress in diabetic bone disorder. Hamada Y, Fujii H, Fukagawa M, Bone 2009 45 Suppl 1 35 S38 19232402
3. Oral administration of quercetin inhibits bone loss in rat model of diabetic osteopenia. Liang W, Luo Z, Ge S, Li M, Du J, Yang M, Yan M, Ye Z, Eur J Pharmacol 2011 670 317 324 10.1016/j.ejphar.2011.08.014 21914440
4. Hyperglycemia-induced oxidative stress in diabetic complications. King GL, Loeken MR, Histochem Cell Biol 2004 122 333 338 10.1007/s00418-004-0678-9 15257460 (Pubitemid 39506591)
5. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, Luo SQ, Biochem Biophys Res Commun 2004 314 197 207 10.1016/j.bbrc.2003.12.073 14715266 (Pubitemid 38058389)
6. Metformin reverses the deleterious effects of high glucose on osteoblast function. Zhen D, Chen Y, Tang X, J Diabetes Complications 2010 24 334 344 10.1016/j.jdiacomp.2009.05.002 19628413
7. Review: the diabetic bone: a cellular and molecular perspective. Blakytny R, Spraul M, Jude EB, Int J Low Extrem Wounds 2011 10 16 32 10.1177/1534734611400256 21444607
8. Protective role of morin, a flavonoid, against high glucose induced oxidative stress mediated apoptosis in primary Rat hepatocytes. Kapoor R, Kakkar P, PLoS One 2012 7 41663 10.1371/journal.pone.0041663 22899998
9. Effect of morin on tissue lipid peroxidation and antioxidant status in 1, 2-dimethylhydrazine induced experimental colon carcinogenesis. Sreedharan V, Venkatachalam KK, Namasivayam N, Invest New Drugs 2009 27 21 30 10.1007/s10637-008-9136-1 18496650
10. Morin augments anticarcinogenic and antiproliferative efficacy against 7,12-dimethylbenz(a)-anthracene induced experimental mammary carcinogenesis. Nandhakumar R, Salini K, Niranjali Devaraj S, Mol Cell Biochem 2012 364 79 92 10.1007/s11010-011-1207-5 22350814
11. Morin attenuates blood pressure and oxidative stress in deoxycorticosterone acetate-salt hypertensive rats: a biochemical and histopathological evaluation. Prahalathan P, Kumar S, Raja B, Metabolism 2012 61 1087 1099 10.1016/j.metabol.2011.12.012 22386933
12. Effects of morin-5'-sulfonic acid sodium salt (NaMSA) on cyclophosphamide-induced changes in oxido-redox state in rat liver and kidney. Merwid-Lad A, Trocha M, Chlebda E, Sozanski T, Magdalan J, Ksiadzyna D, Kopacz M, Kuzniar A, Nowak D, Piesniewska M, et al. Hum Exp Toxicol 2012 31 812 819 10.1177/0960327111431090 22241626
13. Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock. Fang SH, Hou YC, Chang WC, Hsiu SL, Chao PD, Chiang BL, Life Sci 2003 74 743 756 10.1016/j.lfs.2003. 07.017 14654167 (Pubitemid 37494901)
14. Chemopreventive effect of dietary flavonoid morin on chemically induced rat tongue carcinogenesis. Kawabata K, Tanaka T, Honjo S, Kakumoto M, Hara A, Makita H, Tatematsu N, Ushida J, Tsuda H, Mori H, Int J Cancer 1999 83 381 386 10.1002/(SICI)1097-0215(19991029)83:3<381::AID-IJC14>3.0.CO;2-X 10495431 (Pubitemid 29455762)
15. Morin inhibits the growth of human leukemia HL-60 cells via cell cycle arrest and induction of apoptosis through mitochondria dependent pathway. Kuo HM, Chang LS, Lin YL, Lu HF, Yang JS, Lee JH, Chung JG, Anticancer Res 2007 27 395 405 17352259
16. Inhibitory effect of flavonoid derivatives on epstein-barr virus activation and two-stage carcinogenesis of skin tumors. Iwase Y, Takemura Y, Ju-ichi M, Mukainaka T, Ichiishi E, Ito C, Furukawa H, Yano M, Tokuda H, Nishino H, Cancer Lett 2001 173 105 109 10.1016/S0304-3835(01)00615-2 11597783 (Pubitemid 32971926)
17. Inhibitory effects of flavonoids on free radical-induced hemolysis and their oxidative effects on hemoglobin. Kitagawa S, Sakamoto H, Tano H, Chem Pharm Bull (Tokyo) 2004 52 999 1001 10.1248/cpb.52.999 (Pubitemid 41701883)
18. Effect of morin on the levels of circulatory liver markers and redox status in experimental chronic hyperammonaemic rats. Subash S, Subramanian P, Singapore Med J 2008 49 650 655 18756351
19. Morin a flavonoid exerts antioxidant potential in chronic hyperammonemic rats: a biochemical and histopathological study. Subash S, Subramanian P, Mol Cell Biochem 2009 327 153 161 10.1007/s11010-009-0053-1 19238524
20. Effects of polyphenolic natural products on the lipid profiles of rats fed high fat diets. Yugarani T, Tan BK, Teh M, Das NP, Lipids 1992 27 181 186 10.1007/BF02536175 1522762
21. Morin protects heart from beta-adrenergic-stimulated myocardial infarction: an electrocardiographic, biochemical, and histological study in rats. Pogula BK, Maharajan MK, Oddepalli DR, Boini L, Arella M, Sabarimuthu DQ, J Physiol Biochem 2012 68 433 446 10.1007/s13105-012-0157-z 22419268
22. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Sedlak J, Lindsay RH, Anal Biochem 1968 25 192 205 4973948
23. Method for ex-vivo micro-CT analysis of rat bone (proximal tibia, distal femur). Salmon P, Skyscan 2011 [ http://www.skyscan.be/company/UM2011/abstract- 38.pdf ]
24. The mechanisms of alloxan- and streptozotocin-induced diabetes. Lenzen S, Diabetologia 2008 51 216 226 10.1007/s00125-007-0886-7 18087688
25. Effects of combined treatment of insulin and human parathyroid hormone(1-34) on cancellous bone mass and structure in streptozotocin-induced diabetic rats. Suzuki K, Miyakoshi N, Tsuchida T, Kasukawa Y, Sato K, Itoi E, Bone 2003 33 108 114 10.1016/S8756-3282(03)00169-8 12919705 (Pubitemid 36952692)
26. Dietary phenolics: chemistry, bioavailability and effects on health. Crozier A, Jaganath IB, Clifford MN, Nat Prod Rep 2009 26 1001 1043 10.1039/b802662a 19636448
27. Antioxidant phytochemicals against type 2 diabetes. Dembinska-Kiec A, Mykkanen O, Kiec-Wilk B, Mykkanen H, Br J Nutr 2008 99 E Suppl 1 S109 ES117 18503731
28. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Coskun O, Kanter M, Korkmaz A, Oter S, Pharmacol Res 2005 51 117 123 10.1016/j.phrs.2004.06.002 15629256 (Pubitemid 40040541)
29. Bacopa monnieri modulates antioxidant responses in brain and kidney of diabetic rats. Kapoor R, Srivastava S, Kakkar P, Environ Toxicol Pharmacol 2009 27 62 69 10.1016/j.etap.2008.08.007 21783922
30. Bone formation is impaired in a model of type 1 diabetes. Thrailkill KM, Liu L, Wahl EC, Bunn RC, Perrien DS, Cockrell GE, Skinner RA, Hogue WR, Carver AA, Fowlkes JL, et al. Diabetes 2005 54 2875 2881 10.2337/diabetes.54.10.2875 16186388 (Pubitemid 41401082)
31. Mechanism by sambucus nigra extract improves bone mineral density in experimental diabetes. Badescu L, Badulescu O, Badescu M, Ciocoiu M, Evid Based Complement Alternat Med 2012 2012 848269 23024697
32. Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats. Tsirella E, Mavrakanas T, Rager O, Tsartsalis S, Kallaras K, Kokkas B, Mironidou-Tzouveleki M, J Physiol Pharmacol 2012 63 201 204 22653908
33. Oxidative stress in bone remodelling and disease. Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y, Trends Mol Med 2009 15 468 477 10.1016/j.molmed.2009.08.004 19811952
34. Taurine ameliorates alloxan-induced diabetic renal injury, oxidative stress-related signaling pathways and apoptosis in rats. Das J, Sil PC, Amino Acids 2012 43 1509 1523 10.1007/s00726-012-1225-y 22302365
35. The multifaceted associations of hepatobiliary disease and diabetes. Bell DS, Allbright E, Endocr Pract 2007 13 300 312 17599864
36. Ferulsinaic acid modulates SOD, GSH, and antioxidant enzymes in diabetic kidney. Sayed AA, Evid Based Complement Alternat Med 2012 2012 580104 22991571
37. Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chang CC, Chang CY, Huang JP, Hung LM, Chin J Physiol 2012 55 192 201 22784284
38. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T, Arthritis Res 2002 4 281 289 10.1186/ar431 12223101 (Pubitemid 34947141)
39. Interleukin-1 is essential for systemic inflammatory bone loss. Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, van den Berg W, et al. Ann Rheum Dis 2010 69 284 290 10.1136/ard.2008.104786 19196726
40. Protection by albumin against the pro-oxidant actions of phenolic dietary components. Smith C, Halliwell B, Aruoma OI, Food Chem Toxicol 1992 30 483 489 10.1016/0278-6915(92)90099-7 1379971
41. Structure-activity relationships of polymethoxyflavones and other flavonoids as inhibitors of non-enzymic lipid peroxidation. Mora A, Paya M, Rios JL, Alcaraz MJ, Biochem Pharmacol 1990 40 793 797 10.1016/0006-2952(90)90317-E 2386548 (Pubitemid 20246586)
42. Antioxidation of human low density lipoprotein by Morin hydrate. Wu TW, Fung KP, Yang CC, Weisel RD, Life Sci 1995 57 L51 56 10.1016/0024-3205(95)00274- A 7596225
43. Morin hydrate is a plant-derived and antioxidant-based hepatoprotector. Wu TW, Zeng LH, Wu J, Fung KP, Life Sci 1993 53 L213 218 10.1016/0024-3205(93) 90266-6 8366767 (Pubitemid 223041988)
44. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Middleton E Jr, Kandaswami C, Theoharides TC, Pharmacol Rev 2000 52 673 751 11121513
45. Protective effect of quercetin in cisplastin- induced cell injury in the rat kidney. Devipriya S, Shyamaladevi CS, Ind J Pharmacol 1999 31 422 426
46. Dietary flavonoids and flavonoid-rich foods are not associated with risk of type 2 diabetes in postmenopausal women. Nettleton JA, Harnack LJ, Scrafford CG, Mink PJ, Barraj LM, Jacobs DR Jr, J Nutr 2006 136 3039 3045 17116717 (Pubitemid 44878570)
47. Flavonoids and prostate cancer risk: a study in italy. Bosetti C, Bravi F, Talamini R, Parpinel M, Gnagnarella P, Negri E, Montella M, Lagiou P, Franceschi S, La Vecchia C, Nutr Cancer 2006 56 123 127 10.1207/s15327914nc5602- 1 17474856 (Pubitemid 46417670)
48. Isoflavone intake and risk of gastric cancer: a population-based prospective cohort study in japan. Hara A, Sasazuki S, Inoue M, Iwasaki M, Shimazu T, Sawada N, Yamaji T, Tsugane S, Am J Clin Nutr 2012 95 147 154 10.3945/ajcn.111.020479 22170362
49. Beneficial dexa-related effects of natural polyphenols on experimentally-induced diabetes mellitus complications. Pohaci C, Groza M, Mares L, Ciocoiu M, Badescu M, Rev Med Chir Soc Med Nat Iasi 2009 113 838 844 20191842
50. Morin hydrate: a potential antioxidant in minimizing the free-radicals-mediated damage to cardiovascular cells by anti-tumor drugs. Kok LD, Wong YP, Wu TW, Chan HC, Kwok TT, Fung KP, Life Sci 2000 67 91 99 10.1016/S0024-3205(00)00605-6 10896033 (Pubitemid 30368626)
51. Morin (2',3,4',5,7-pentahydroxyflavone) protected cells against gamma-radiation-induced oxidative stress. Zhang R, Kang KA, Kang SS, Park JW, Hyun JW, Basic Clin Pharmacol Toxicol 2011 108 63 72 10.1111/j.1742-7843.2010. 00629.x 20807219
52. Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat. Galvez J, Coelho G, Crespo ME, Cruz T, Rodriguez-Cabezas ME, Concha A, Gonzalez M, Zarzuelo A, Aliment Pharmacol Ther 2001 15 2027 2039 10.1046/j.1365-2036.2001.01133.x 11736735 (Pubitemid 34014359)
53. Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo. Kim JW, Lee JH, Hwang BY, Mun SH, Ko NY, Kim do K, Kim B, Kim HS, Kim YM, Choi WS, Biochem Pharmacol 2009 77 1506 1512 10.1016/j.bcp.2009.01.019 19426688
54. Flavonoid combinations cause synergistic inhibition of proinflammatory mediator secretion from lipopolysaccharide-induced RAW 264.7 Cells. Harasstani OA, Moin S, Tham CL, Liew CY, Ismail N, Rajajendram R, Harith HH, Zakaria ZA, Mohamad AS, Sulaiman MR, Israf DA, Inflamm Res 2010 59 711 721 10.1007/s00011-010-0182-8 20221843
55. Effects of morin on an experimental model of acute colitis in rats. Ocete MA, Galvez J, Crespo ME, Cruz T, Gonzalez M, Torres MI, Zarzuelo A, Pharmacology 1998 57 261 270 10.1159/000028250 9742291 (Pubitemid 28444868)
56. Morin inhibits interleukin-1beta-induced nitric oxide and prostaglandin E2 production in human chondrocytes. Chen WP, Wang YL, Tang JL, Hu PF, Bao JP, Wu LD, Int Immunopharmacol 2012 12 447 452 10.1016/j.intimp.2011.12.024 22244821